
Published
Eloralintide vs retatrutide: different hormone targets, different evidence
An amylin medicine and a triple-receptor medicine have different evidence. Their headline weight-loss percentages cannot identify a winner.
11 min readRead story
2 stories to explore.

An amylin medicine and a triple-receptor medicine have different evidence. Their headline weight-loss percentages cannot identify a winner.

Eloralintide targets amylin signaling. Its human trial results, side effects and ongoing research deserve a clear explanation.